The Nuclear Export Protein Exportin-1 in Solid Malignant Tumours: From Biology to Clinical Trials

Overview

Journal Clin Transl Med

Publisher Wiley

Specialty General Medicine

Date 2024 May 24

PMID 38783482

Authors

Chuanxi Lai

Lingna Xu

Sheng Dai

Affiliations

Soon will be listed here.

Abstract

Background: Exportin-1 (XPO1), a crucial protein regulating nuclear-cytoplasmic transport, is frequently overexpressed in various cancers, driving tumor progression and drug resistance. This makes XPO1 an attractive therapeutic target. Over the past few decades, the number of available nuclear export-selective inhibitors has been increasing. Only KPT-330 (selinexor) has been successfully used for treating haematological malignancies, and KPT-8602 (eltanexor) has been used for treating haematologic tumours in clinical trials. However, the use of nuclear export-selective inhibitors for the inhibition of XPO1 expression has yet to be thoroughly investigated in clinical studies and therapeutic outcomes for solid tumours.

Methods: We collected numerous literatures to explain the efficacy of XPO1 Inhibitors in preclinical and clinical studies of a wide range of solid tumours.

Results: In this review, we focus on the nuclear export function of XPO1 and results from clinical trials of its inhibitors in solid malignant tumours. We summarized the mechanism of action and therapeutic potential of XPO1 inhibitors, as well as adverse effects and response biomarkers.

Conclusion: XPO1 inhibition has emerged as a promising therapeutic strategy in the fight against cancer, offering a novel approach to targeting tumorigenic processes and overcoming drug resistance. SINE compounds have demonstrated efficacy in a wide range of solid tumours, and ongoing research is focused on optimizing their use, identifying response biomarkers, and developing effective combination therapies.

Key Points: Exportin-1 (XPO1) plays a critical role in mediating nucleocytoplasmic transport and cell cycle. XPO1 dysfunction promotes tumourigenesis and drug resistance within solid tumours. The therapeutic potential and ongoing researches on XPO1 inhibitors in the treatment of solid tumours. Additional researches are essential to address safety concerns and identify biomarkers for predicting patient response to XPO1 inhibitors.

Citing Articles

Selinexor in the treatment of liposarcoma: from preclinical evidence to clinical practice.

Remiszewski P, Gaik W, Skora A, Waz J, Filipek K, Pisklak A Med Oncol. 2025; 42(4):94.

PMID: 40056309 DOI: 10.1007/s12032-025-02651-2.

Advances in the role of membrane-bound transcription factors in carcinogenesis and therapy.

Deng J, Zhou J, Jiang B Discov Oncol. 2024; 15(1):559.

PMID: 39404930 PMC: 11480308. DOI: 10.1007/s12672-024-01414-1.

The nuclear export protein exportin-1 in solid malignant tumours: From biology to clinical trials.

Lai C, Xu L, Dai S Clin Transl Med. 2024; 14(5):e1684.

PMID: 38783482 PMC: 11116501. DOI: 10.1002/ctm2.1684.

References

Cheng Y, Holloway M, Nguyen K, McCauley D, Landesman Y, Kauffman M . XPO1 (CRM1) inhibition represses STAT3 activation to drive a survivin-dependent oncogenic switch in triple-negative breast cancer. Mol Cancer Ther. 2014; 13(3):675-86. PMC: 3954411. DOI: 10.1158/1535-7163.MCT-13-0416. View

Wach J, Guttinger S, Kutay U, Gademann K . The cytotoxic styryl lactone goniothalamin is an inhibitor of nucleocytoplasmic transport. Bioorg Med Chem Lett. 2010; 20(9):2843-6. DOI: 10.1016/j.bmcl.2010.03.049. View

Zhu Z, Liu J, Yang C, Zhao M, Xiong Z . XPO1 inhibitor KPT-330 synergizes with Bcl-xL inhibitor to induce cancer cell apoptosis by perturbing rRNA processing and Mcl-1 protein synthesis. Cell Death Dis. 2019; 10(6):395. PMC: 6529444. DOI: 10.1038/s41419-019-1627-9. View

Niu M, Wu S, Mao L, Yang Y . CRM1 is a cellular target of curcumin: new insights for the myriad of biological effects of an ancient spice. Traffic. 2013; 14(10):1042-52. DOI: 10.1111/tra.12090. View

Golomb L, Bublik D, Wilder S, Nevo R, Kiss V, Grabusic K . Importin 7 and exportin 1 link c-Myc and p53 to regulation of ribosomal biogenesis. Mol Cell. 2012; 45(2):222-32. PMC: 3270374. DOI: 10.1016/j.molcel.2011.11.022. View

Santos S, Junqueira M, Francisco G, Vilanova M, Magalhaes A, Baruffi M . O-glycan sialylation alters galectin-3 subcellular localization and decreases chemotherapy sensitivity in gastric cancer. Oncotarget. 2016; 7(50):83570-83587. PMC: 5347789. DOI: 10.18632/oncotarget.13192. View

Kirli K, Karaca S, Dehne H, Samwer M, Pan K, Lenz C . A deep proteomics perspective on CRM1-mediated nuclear export and nucleocytoplasmic partitioning. Elife. 2015; 4. PMC: 4764573. DOI: 10.7554/eLife.11466. View

Farren M, Hennessey R, Shakya R, Elnaggar O, Young G, Kendra K . The Exportin-1 Inhibitor Selinexor Exerts Superior Antitumor Activity when Combined with T-Cell Checkpoint Inhibitors. Mol Cancer Ther. 2017; 16(3):417-427. PMC: 5407496. DOI: 10.1158/1535-7163.MCT-16-0498. View

Martini S, Zuco V, Tortoreto M, Percio S, Campi E, El Bezawy R . miR-34a-Mediated Survivin Inhibition Improves the Antitumor Activity of Selinexor in Triple-Negative Breast Cancer. Pharmaceuticals (Basel). 2021; 14(6). PMC: 8227962. DOI: 10.3390/ph14060523. View

10.

Lu C, Shao C, Cobos E, Singh K, Gao W . Chemotherapeutic sensitization of leptomycin B resistant lung cancer cells by pretreatment with doxorubicin. PLoS One. 2012; 7(3):e32895. PMC: 3296751. DOI: 10.1371/journal.pone.0032895. View

11.

Yang G, Guan W, Cao Z, Guo W, Xiong G, Zhao F . Integrative Genomic Analysis of Gemcitabine Resistance in Pancreatic Cancer by Patient-derived Xenograft Models. Clin Cancer Res. 2021; 27(12):3383-3396. DOI: 10.1158/1078-0432.CCR-19-3975. View

12.

Chuang L, Matsuo J, Douchi D, Bte Mawan N, Ito Y . RUNX3 in Stem Cell and Cancer Biology. Cells. 2023; 12(3). PMC: 9913995. DOI: 10.3390/cells12030408. View

13.

Santivasi W, Wang H, Wang T, Yang Q, Mo X, Brogi E . Association between cytosolic expression of BRCA1 and metastatic risk in breast cancer. Br J Cancer. 2015; 113(3):453-9. PMC: 4522623. DOI: 10.1038/bjc.2015.208. View

14.

Gravina G, Tortoreto M, Mancini A, Addis A, Di Cesare E, Lenzi A . XPO1/CRM1-selective inhibitors of nuclear export (SINE) reduce tumor spreading and improve overall survival in preclinical models of prostate cancer (PCa). J Hematol Oncol. 2014; 7:46. PMC: 4283114. DOI: 10.1186/1756-8722-7-46. View

15.

Thakor N, Janathia B . Plumbagin: A Potential Candidate for Future Research and Development. Curr Pharm Biotechnol. 2021; 23(15):1800-1812. DOI: 10.2174/1389201023666211230113146. View

16.

von Fallois M, Kosyna F, Mandl M, Landesman Y, Dunst J, Depping R . Selinexor decreases HIF-1α via inhibition of CRM1 in human osteosarcoma and hepatoma cells associated with an increased radiosensitivity. J Cancer Res Clin Oncol. 2021; 147(7):2025-2033. PMC: 8164574. DOI: 10.1007/s00432-021-03626-2. View

17.

Shin D, Jeon J, Jeong M, Suh H, Kim S, Kim H . VDUP1 mediates nuclear export of HIF1alpha via CRM1-dependent pathway. Biochim Biophys Acta. 2007; 1783(5):838-48. DOI: 10.1016/j.bbamcr.2007.10.012. View

18.

Macara I . Transport into and out of the nucleus. Microbiol Mol Biol Rev. 2001; 65(4):570-94, table of contents. PMC: 99041. DOI: 10.1128/MMBR.65.4.570-594.2001. View

19.

Wang J, Wang X, Zheng B, Wang Y, Wang X, Liang B . Curcumin inhibits the growth via Wnt/β-catenin pathway in non-small-cell lung cancer cells. Eur Rev Med Pharmacol Sci. 2018; 22(21):7492-7499. DOI: 10.26355/eurrev_201811_16290. View

20.

Mori K, Hirao E, Toya Y, Oshima Y, Ishikawa F, Nose K . Competitive nuclear export of cyclin D1 and Hic-5 regulates anchorage dependence of cell growth and survival. Mol Biol Cell. 2008; 20(1):218-32. PMC: 2613120. DOI: 10.1091/mbc.e08-04-0428. View